AUS
NZ
UK
CA
USA
IND
Highlights
- Exenatide's Role in Alzheimer's Simulation: Invex Therapeutics has successfully tested exenatide, a diabetes drug, in a 3D human brain model to assess its potential in delaying Alzheimer’s disease (AD). This marks the first demonstration of the drug's benefits in a simulated AD environment.
- Impact on Cell Viability: In collaboration with Tessara, Invex observed that exenatide increased cell viability by 24% at low doses and 45% at moderate doses, especially in conditions mimicking ferroptosis, a cell death mechanism linked to AD.
- Research Significance: While the study does not claim to cure Alzheimer’s, it suggests exenatide could enhance brain resilience, particularly in areas affected by AD, potentially offering new insights into AD treatment.
Invex Therapeutics (ASX:IXC) has made significant progress in its research into Alzheimer’s disease (AD) treatment, utilizing exenatide, a drug originally developed for diabetes, in a cutting-edge 3D brain model. The study, conducted in partnership with Tessara, a private company specializing in computerized models of Alzheimer's-affected human brains, shows promising results for the drug’s ability to enhance cell survival in AD simulations.
Exenatide, a GLP-1 receptor agonist (GLP-1RA), has previously been associated with potential benefits in Alzheimer's patients, particularly those who were also managing diabetes. The drug is known to affect insulin regulation but is now being explored for its potential to bolster the resilience of brain cells in the context of Alzheimer's.
Key Findings
The study revealed that exenatide significantly improved cell viability in the 3D brain model. At a low dose, the drug increased cell survival by approximately 24% in conditions designed to replicate the challenges faced by AD patients, such as cell death. A moderate dose of exenatide showed an even more striking result, with a 45% increase in cell viability in conditions resembling ferroptosis, a form of cell death linked to the buildup of brain plaques seen in Alzheimer's.
These findings underscore the potential of exenatide to support the physical integrity of brain cells in Alzheimer’s, though the drug is not a cure. Instead, the research suggests that it may help delay the onset or progression of the disease by promoting cell resilience in key areas of the brain affected by AD pathology.
Clinical Relevance and Next Steps
Although the study’s findings are promising, they remain in the early stages. The results were based on a simulated model, and further clinical studies will be needed to confirm exenatide’s efficacy in real-world Alzheimer’s patients. Additionally, while the data provides a solid foundation for further investigation, it is likely that investors and researchers will seek more detailed results before making broader conclusions about the drug's potential.
Invex’s share price remained largely unchanged following the announcement, possibly reflecting investor caution until additional data is released. Nonetheless, these early-stage findings could have significant implications for the future of Alzheimer’s treatments and may open up new pathways for therapeutic exploration in neurological diseases beyond Alzheimer’s.
As the research progresses, continued collaboration between Invex and Tessara may provide crucial insights into the broader applications of exenatide and other GLP-1 receptor agonists in the treatment of neurodegenerative diseases.
